Allogene Therapeutics Inc (NASDAQ: ALLO) on Tuesday, plunged -0.42% from the previous trading day, before settling in for the closing price of $2.36. Within the past 52 weeks, ALLO’s price has moved between $2.01 and $5.78.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -27.79% over the past five years. The company achieved an average annual earnings per share of 31.97%. With a float of $136.91 million, this company’s outstanding shares have now reached $209.11 million.
Allogene Therapeutics Inc (ALLO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Allogene Therapeutics Inc is 34.53%, while institutional ownership is 51.23%. The most recent insider transaction that took place on Jun 18 ’24, was worth 42,488. In this transaction Director of this company sold 18,641 shares at a rate of $2.28, taking the stock ownership to the 166,765 shares. Before that another transaction happened on May 30 ’24, when Company’s Director sold 11,200 for $2.34, making the entire transaction worth $26,181. This insider now owns 255,253 shares in total.
Allogene Therapeutics Inc (ALLO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 31.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.00% during the next five years compared to 22.18% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Allogene Therapeutics Inc (ALLO) is currently performing well based on its current performance indicators. A quick ratio of 12.25 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5460.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (NASDAQ: ALLO) saw its 5-day average volume 1.91 million, a negative change from its year-to-date volume of 2.66 million. As of the previous 9 days, the stock’s Stochastic %D was 13.22%. Additionally, its Average True Range was 0.23.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 12.98%, which indicates a significant decrease from 13.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.75% in the past 14 days, which was lower than the 73.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.58, while its 200-day Moving Average is $3.24. Nevertheless, the first resistance level for the watch stands at $2.42 in the near term. At $2.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.55. If the price goes on to break the first support level at $2.28, it is likely to go to the next support level at $2.22. The third support level lies at $2.15 if the price breaches the second support level.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
Market capitalization of the company is 491.41 million based on 209,000K outstanding shares. Right now, sales total 100 K and income totals -327,270 K. The company made 20 K in profit during its latest quarter, and -65,000 K in sales during its previous quarter.
